Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicitie

被引：44

作者：

Guha, Avirup ^{[1
]}

Armanious, Merna ^{[2
,3
]}

Fradley, Michael G. ^{[2
,3
]}

机构：

[1] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA

[2] Univ S Florida, Div Cardiovasc Med, Cardiooncol Program, 2 Tampa Gen Circle, Tampa, FL 33606 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Cardiooncol Program, 12902 USF Magnolia Dr, Tampa, FL 33612 USA

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2019年 / 29卷 / 01期

关键词：

Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; Proteasome inhibitors; CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; HISTONE DEACETYLASE INHIBITORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; PLATINUM-BASED CHEMOTHERAPY; ARTERIAL OCCLUSIVE DISEASE; DABRAFENIB PLUS TRAMETINIB; MISMATCH REPAIR-DEFICIENT;

D O I：

10.1016/j.tcm.2018.06.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：29 / 39

页数：11

共 235 条

[11]

[Anonymous], 2017, J CLIN ONCOL S15

[12] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[13] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[14] Electrophysiologic Toxicity of Chemoradiation [J].

Armanious, Merna A. ;

Mishra, Shreya ;

Fradley, Michael G. .

CURRENT ONCOLOGY REPORTS, 2018, 20 (06)

[15] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Marit, Gerald ;

Caillot, Denis ;

Moreau, Philippe ;

Facon, Thierry ;

Stoppa, Anne Marie ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Garderet, Laurent ;

Decaux, Olivier ;

Leyvraz, Serge ;

Vekemans, Marie-Christiane ;

Voillat, Laurent ;

Michallet, Mauricette ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Roussel, Murielle ;

Leleu, Xavier ;

Mathiot, Claire ;

Payen, Catherine ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791

[16] Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia [J].

Aue, Georg ;

Lozier, Jay Nelson ;

Tian, Xin ;

Cullinane, Ann M. ;

Soto, Susan ;

Samsel, Leigh ;

McCoy, Philip ;

Wiestner, Adrian .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (10) :835-840

[17] Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients [J].

Avet-Loiseau, Herve ;

Bahlis, Nizar J. ;

Chng, Wee-Joo ;

Masszi, Tamas ;

Viterbo, Luisa ;

Pour, Ludek ;

Ganly, Peter ;

Palumbo, Antonio ;

Cavo, Michele ;

Langer, Christian ;

Pluta, Andrzej ;

Nagler, Arnon ;

Kumar, Shaji ;

Ben-Yehuda, Dina ;

Rajkumar, S. Vincent ;

San-Miguel, Jesus ;

Berg, Deborah ;

Lin, Jianchang ;

van de Velde, Helgi ;

Esseltine, Dixie-Lee ;

di Bacco, Alessandra ;

Moreau, Philippe ;

Richardson, Paul G. .

BLOOD, 2017, 130 (24) :2610-2618

[18] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[19] New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma [J].

Behling, Juliane ;

Kaes, Joachim ;

Muenzel, Thomas ;

Grabbe, Stephan ;

Loquai, Carmen .

MELANOMA RESEARCH, 2017, 27 (02) :155-158

[20] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

← 1 2 3 4 5 6 7 8 9 10 →